Brepocitinib VALOR Trial Shows Positive Dermatomyositis Data
In the Phase 3 VALOR trial (n=241), brepocitinib 30 mg once-daily delivered a 15.3-point greater improvement in mean Total...
MoonLake Reveals New Sonelokimab HS Phase 3 Trial Results
At Week 40 in the Phase 3 VELA program for moderate-to-severe hidradenitis suppurativa (HS), sonelokimab achieved a 62% HiSCR75...
The Bone and Muscle Safety Gap That GLP-1 Megastudies Weren’t Designed to Fill
Lilly and Novo have already won the weight-loss efficacy war. The next drug approval battle is being fought on...
Spectral & Vantive Publish Tigris Trial Results in Lancet
In the Phase 3 Tigris trial of 157 adults with endotoxic septic shock, polymyxin B hemoadsorption (PMX) achieved a...
Minerva Presents Safety Trial Data on Roluperidone, Olanzapine
Minerva Neurosciences reported that an open-label safety study of roluperidone coadministered with olanzapine showed no clinically significant adverse effects...
LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial
Phase 2 results for LB-102 showed statistically significant reductions in PANSS total score across all doses with onset by...
BEAM-302 Trial Shows Compelling Data for AATD Treatment
Beam’s Phase 1/2 readout for BEAM-302 in severe alpha-1 antitrypsin deficiency (AATD) delivered clean, quantitative signals: at the 60...
C4 Therapeutics Begins Phase 1b Trial for Multiple Myeloma
C4 Therapeutics has dosed the first patient in a Phase 1b study assessing cemsidomide plus dexamethasone in combination with...
The Wearable Gap: Why Sensors Are Outrunning the Trials That Use Them
Wearables are generating physiological data at a scale clinical trials have never seen before. But a March 2026 review...
Aclaris Announces Phase 2a Trial Results for ATI-2138 at AAD
Aclaris will present new results from its open-label Phase 2a study of ATI-2138, an oral covalent inhibitor of ITK...